Cullinan Oncology goes full circle, scoring $275M for sharing the load on EGFR inhibitor with original developer

Only a few months after CEO Nadim Ahmed came over from Bristol Myers Squibb and joined as the top brass at the cancer-focused biotech Cullinan …

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER

Cul­li­nan On­col­o­gy goes full cir­cle, scor­ing $275M for shar­ing the load on EGFR in­hibitor with orig­i­nal de­vel­op­er